###begin article-title 0
###xml 79 85 79 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC1A4</italic>
###xml 87 94 87 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC1A5 </italic>
###xml 128 134 128 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC6A5</italic>
###xml 136 143 136 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC6A9 </italic>
Association study of polymorphisms in the neutral amino acid transporter genes SLC1A4, SLC1A5 and the glycine transporter genes SLC6A5, SLC6A9 with schizophrenia
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 266 272 266 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC1A4</italic>
###xml 274 281 274 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC1A5 </italic>
###xml 340 346 340 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC6A5</italic>
###xml 348 355 348 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC6A9 </italic>
Based on the glutamatergic dysfunction hypothesis for schizophrenia pathogenesis, we have been performing systematic association studies of schizophrenia with the genes involved in glutametergic transmission. We report here association studies of schizophrenia with SLC1A4, SLC1A5 encoding neutral amino acid transporters ASCT1, ASCT2, and SLC6A5, SLC6A9 encoding glycine transporters GLYT2, GLYT1, respectively.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
We initially tested the association of 21 single nucleotide polymorphisms (SNPs) distributed in the four gene regions with schizophrenia using 100 Japanese cases-control pairs and examined allele, genotype and haplotype association with schizophrenia. The observed nominal significance were examined in the full-size samples (400 cases and 420 controls).
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 89 91 89 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 110 112 110 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 124 130 124 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC1A4</italic>
###xml 138 140 138 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 159 161 159 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 173 179 173 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC6A5</italic>
###xml 296 298 296 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 310 317 310 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC1A4 </italic>
###xml 332 334 332 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 346 352 346 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC6A5</italic>
###xml 509 516 509 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC6A5 </italic>
###xml 578 580 578 580 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
We observed nominally significant single-marker associations with schizophrenia in SNP2 (P = 0.021) and SNP3 (P = 0.029) of SLC1A4, SNP1 (P = 0.009) and SNP2 (P = 0.022) of SLC6A5. We also observed nominally significant haplotype associations with schizophrenia in the combinations of SNP2-SNP7 (P = 0.037) of SLC1A4 and SNP1-SNP4 (P = 0.043) of SLC6A5. We examined all of the nominal significance in the Full-size Sample Set, except one haplotype with insufficient LD. The significant association of SNP1 of SLC6A5 with schizophrenia was confirmed in the Full-size Sample Set (P = 0.018).
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 102 108 102 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC6A5</italic>
###xml 118 124 118 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC1A4</italic>
###xml 126 133 126 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC1A5 </italic>
###xml 137 144 137 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC6A9 </italic>
We concluded that at least one susceptibility locus for schizophrenia may be located within or nearby SLC6A5, whereas SLC1A4, SLC1A5 and SLC6A9 are unlikely to be major susceptibility genes for schizophrenia in the Japanese population.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 95 96 95 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 173 174 173 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 843 844 843 844 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 845 846 845 846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1052 1053 1052 1053 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1054 1055 1054 1055 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1250 1251 1250 1251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
Schizophrenia is a devastating mental disorder that affects about 1% of worldwide populations [1], and genetic factors are known to play a crucial role in its pathogenesis [2]. The successful treatment with dopamine antagonists on the positive symptomatology of the disease suggests a crucial role of dopamine in the pathophysiology of schizophrenia. However, due to the poor effects of dopamine antagonists against the negative and cognitive symptoms of schizophrenia, other neurotransmitter systems than dopamine, such as glutamate are suggested to be involved in the pathogenesis of schizophrenia. Based on the fact that phencyclidine (PCP), the antagonist of N-methyl-D-aspartate (NMDA) glutamate receptor, induces schizophreniform psychosis, a glutamatergic dysfunction hypothesis has been proposed for the pathogenesis of schizophrenia [3-5]. This hypothesis has been supported by recent multiple reports of significant association of schizophrenia with glutamate receptor genes and with the genes related to glutamatergic transmission [Review, [6,7]]. The dopamine and glutamate hypothesis of schizophrenia are not independent, and in fact, glutamate-dopamine interaction has been supported by many preclinical and clinical findings [Review, [8]].
###end p 11
###begin p 12
###xml 436 437 436 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 438 440 438 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 498 505 498 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC1A2 </italic>
###xml 509 515 509 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC1A6</italic>
###xml 586 588 586 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 589 591 589 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
Other synaptic elements related to glutamate, such as transporters, also potentially affect glutamatergic neurotransmission. Excitatory amino acid transporters (EAATs) maintain extracellular glutamate concentrations within physiological levels by reuptaking synaptically released glutamate. Abnormalities of mRNA expression of EAATs were reported in the thalamus, prefrontal cortex, parahippocampal gyrus and striatum in schizophrenia [9-12]. Recently, we have reported the positive association of SLC1A2 and SLC1A6, the genes encoding EAAT2 and EAAT4, respectively with schizophrenia [13,14], providing support for the potential important roles of EAATs in schizophrenia.
###end p 12
###begin p 13
###xml 185 187 185 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 188 190 188 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 535 537 535 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 538 540 538 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 831 833 831 833 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1035 1037 1035 1037 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
Neutral amino acid transporters (ASCTs), which transport neutral amino acid (alanine, serine, cysteine and threonin) were identified based on nucleotide sequence homology to the EAATs [15,16]. The amino acid identity between EAATs and ASCTs is 40-44%. The functions of ASCTs in glutamate transmission have also been reported. ASCT1 not only mediates the efflux of glutamate from the neuron into the synaptic junction via Calcium-independent release, but also mediates the efflux of L-serine from glial cells and its uptake by neurons [17-19]. L-serine is used for syntheses of various biomolecules, including the co-agonists at NMDA glutamate receptor, D-serine and glycine. ASCT2 appears to play an important role in the glutamine-glutamate cycle between neurons and glia by facilitation the efflux of glutamine from glial cells [20]. Recently, Weis et al. reported significant decrease in ASCT1 immunoreactivity in the cingulate cortex, white matter, and striking loss of ASCT1 immunoreactivity in the hippocampus in schizophrenia. [21].
###end p 13
###begin p 14
###xml 281 283 281 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 629 631 629 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
Glycine acts as an obligatory co-agonist at NMDA glutamate receptor to promote NMDA receptor function. In the central system, the actions of glycine are terminated by its rapid uptake into the nerve terminal and adjacent glial cells via high-affinity glycine transporters (GLYTs) [22]. Therefore, increasing synaptic level of glycine by inhibiton of its uptake could lead to enhance the activation of NMDA receptor. Both preclinical and clinical evidence have provided support for the utility of this modulatory approach, as well as the potential therapeutic value of GLYT1 inhibitors in the treatment of schizophrenia [Review, [23]]. Therefore the ASCTs and GLYTs genes are strong candidates for schizophrenia, as well as glutamate receptor and glutamate transporter genes.
###end p 14
###begin p 15
###xml 101 107 101 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC1A4</italic>
###xml 109 115 109 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC1A5</italic>
###xml 117 124 117 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC6A5 </italic>
###xml 128 135 128 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC6A9 </italic>
In this study we report association studies of schizophrenia with total 21 SNPs distributed in genes SLC1A4, SLC1A5, SLC6A5 and SLC6A9 that encoding the neutral amino acid transporters ASCT1, ASCT2 and the glycine transporters GLYT2, GLYT1, respectively. SNPs were selected to cover the entire gene regions by linkage disequilibria (LD). To enhance the detection power of the study, we also examined the haplotype associations with the disease.
###end p 15
###begin title 16
Methods
###end title 16
###begin title 17
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human subjects
###end title 17
###begin p 18
###xml 655 657 655 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1047 1049 1047 1049 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 551 559 <span type="species:ncbi:9606">patients</span>
###xml 664 672 <span type="species:ncbi:9606">patients</span>
Blood samples were obtained from unrelated Japanese individuals who had provided written informed consent. We used 400 cases (mean age 47.2; 44.8% female) recruited from hospitals in Kyushu and Aichi areas and 420 unrelated controls (mean age 43.6; 44.0% female) recruited from the Kyushu and Aichi areas. We initially tested the association of the genes with schizophrenia using the Screening Sample Set: 100 out of 400 cases (mean age 49.5; 44.0% female) and 100 out of 420 controls (mean age 51.2; 44.0% female) recruited from the Kyushu area. All patients were diagnosed by the Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV criteria [24]. The patients are all consecutive inpatients. The schizophrenia diagnoses were confirmed by several psychiatrists. We used another 16 healthy Japanese samples to test the frequencies of the candidate SNPs selected from the database. This study was approved by the Ethics Committee of Kyushu University, Faculty of Medicine. DNA samples were extracted from leukocytes by standard methods [25].
###end p 18
###begin title 19
SNP selection
###end title 19
###begin p 20
###xml 66 68 66 68 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 154 156 154 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 651 653 651 653 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D </italic>
We retrieved the primary SNP information from the dbSNP database [26]. Assuming the same size of the half length of LD (60 kb) as reported in Caucasians [27], we initially intended to select common SNPs every 30 kb in the three genes including all of the exonic SNPs. We tested the frequencies of the candidate SNPs, in the 16 healthy Japanese samples by the direct sequencing method. Out of them, common SNPs with minor allele frequencies over 10% were selected for further analyses. The SNPs in which significant deviation from Hardy-Weinberg equilibrium (HWE) observed in the 100 control samples were replaced by another SNP nearby. Since LD gaps (D ' < 0.3) were observed in the initial SNP set after the LD analyses described below, we selected additional SNPs to fill the LD gaps.
###end p 20
###begin p 21
###xml 112 118 112 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC1A4</italic>
###xml 294 300 294 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC1A5</italic>
###xml 391 397 391 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC6A5</italic>
###xml 508 514 508 514 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC6A9</italic>
###xml 612 613 612 613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
We finally selected the following 21 common SNPs distributed across the gene regions for further analyses: 7 of SLC1A4, SNP1, rs10211524; SNP2, rs7559202; SNP3, rs7592468; SNP4, rs3732062; SNP5, novel SNP in intron 3 (located on 33bp 5' to SNP rs7583682); SNP6, rs759458; SNP7, rs2540969, 5 of SLC1A5, SNP1, rs918486; SNP2, rs3027956; SNP3, rs313853; SNP4, rs2070246; SNP5, rs11673198, 6 of SLC6A5, SNP1, rs894747; SNP2, rs3781742; SNP3, rs3758807; SNP4, rs3819252; SNP5, rs2000959, SNP6, rs1792970 and 3 of SLC6A9, SNP1, rs783307; SNP2, rs2248829; SNP3, rs7555. The locations of the 21 SNPs are shown in Figure 1.
###end p 21
###begin p 22
###xml 0 61 0 61 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Genomic organizations of each gene and locations of the SNPs.</bold>
###xml 66 73 66 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC1A4 </italic>
###xml 122 129 122 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC1A5 </italic>
###xml 178 185 178 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC6A5 </italic>
###xml 237 244 237 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC6A9 </italic>
Genomic organizations of each gene and locations of the SNPs. (a) SLC1A4 spans over 34 kb and is composed of 8 exons. (b) SLC1A5 spans over 14 kb and is composed of 8 exons. (c) SLC6A5 spans over 55.6 kb and is composed of 16 exons. (d) SLC6A9 spans over 19.8 kb and is composed of 14 exons. Exons are shown as vertical bars with exon numbers. SNPs we analyzed are indicated by circles. Exonic SNPs are indicated by filled circles.
###end p 22
###begin title 23
Genotyping
###end title 23
###begin p 24
###xml 83 85 83 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 209 210 209 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 248 255 248 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC1A5 </italic>
###xml 386 392 386 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC1A5</italic>
###xml 427 434 427 434 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC6A5 </italic>
###xml 584 586 584 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 651 653 651 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
The 21 SNPs were amplified as individual fragments by PCR as previously described [14]. The nucleotide sequences of each primer, PCR conditions and genotyping methods for each SNP are shown in Additional File 1. Because of the GC rich sequences of SLC1A5 region, we used Fail Safe PCR system (Epicentre Technologies) to optimize the PCR conditions when amplified SNP1, SNP2 and SNP5 of SLC1A5. We genotyped samples for SNP5 of SLC6A5 by polymerase chain reaction/restriction fragment length polymorphism (PCR-RFLP) and the other 20 SNPs by direct sequencing, as previously described [28]. The raw data of direct sequencing were compiled on PolyPhred [29] and/or Mutation Surveyor (SoftGenetics LLC).
###end p 24
###begin title 25
Statistical analyses
###end title 25
###begin p 26
###xml 137 138 135 136 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 368 372 366 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D ' </italic>
###xml 447 449 445 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 456 459 454 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D' </italic>
###xml 558 560 556 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 654 656 652 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 734 736 732 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 841 843 839 841 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
To control genotyping errors, Hardy-Weinberg equilibrium (HWE) for the genotype frequencies was checked in the control samples by the chi2-test (d.f. = 1). We evaluated the statistical differences in genotype and allele frequencies between cases and controls by Fisher's exact probability test. The magnitude of linkage disequilibrium (LD) was evaluated by caculating D ' using the haplotype frequencies estimated by the EH program, version 1.14 [30], and D' is represented graphically using the software Graphical Overview of Linkage Disequilibrium (GOLD) [31]. Statistical analysis of the haplotype association was carried out as previously described [32]. The significance level for all statistical tests was 0.05. We adjusted the P values of association studies for multiplicity using a false discovery rate (FDR) controlling procedure [33].
###end p 26
###begin title 27
Results
###end title 27
###begin title 28
Genotyping and SNP association analyses
###end title 28
###begin p 29
###xml 63 69 63 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC1A4</italic>
###xml 82 88 82 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC1A5</italic>
###xml 102 109 102 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC6A5 </italic>
###xml 125 132 125 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC6A9 </italic>
###xml 301 307 301 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC1A4</italic>
###xml 309 315 309 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC1A5</italic>
###xml 317 324 317 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC6A5 </italic>
###xml 328 335 328 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC6A9 </italic>
###xml 446 448 446 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
We selected total 21 SNPs at an average interval of 7.8 kb for SLC1A4, 4.5 kb for SLC1A5, 14.2 kb for SLC6A5 and 18.9 kb for SLC6A9 to cover each entire gene region with LD. Since the average allele frequencies of the SNPs are 0.35, 0.30, 0.37 and 0.30 respectively, the expected detection powers for SLC1A4, SLC1A5, SLC6A5 and SLC6A9 are 0.84, 0.82, 0.84 and 0.82, respectively, under the multiplicative model with genotype relative risk = 1.8 [34]. Considering the high expected detection powers, we initially tested the single-marker association of the 21 SNPs with schizophrenia using the Screening Sample Set (100 cases and 100 controls) by the method described above, and investigated the association in the Full-size Sample Set (400 cases and 420 controls) only for the SNPs that showed significant single-marker or haplotype association with schizophrenia in the Screening Sample Set.
###end p 29
###begin p 30
###xml 6 7 6 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 302 309 302 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC1A4 </italic>
###xml 310 312 310 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 321 323 321 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 395 402 395 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC6A5 </italic>
###xml 403 405 403 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 414 416 414 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 522 529 522 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC1A4 </italic>
###xml 543 549 543 549 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC6A5</italic>
Table 1 shows the results of genotype and allele frequencies of SNPs in 100 case and 100 control samples. No significant deviation from HWE in control samples was observed in these SNPs (data not shown). We observed significant associations with schizophrenia in allele frequencies of SNP2 and SNP3 of SLC1A4 (P = 0.021, P = 0.029, respectively), and in genotype frequencies of SNP1 and SNP2 of SLC6A5 (P = 0.009, P = 0.022, respectively), although none of them survived after controlling the FDR at level 0.05 (n = 7 for SLC1A4 and n = 6 for SLC6A5).
###end p 30
###begin p 31
Genotype and allele frequencies of SNPs in each gene in the Screening Sample Set (100 cases and 100 controls)
###end p 31
###begin p 32
*Fisher's exact probability tests, case vs. control (2 x 3).
###end p 32
###begin p 33
**Fisher's exact probability tests, case vs. control (2 x 2).
###end p 33
###begin title 34
Pairwise linkage disequilibrium and haplotype association analyses
###end title 34
###begin p 35
###xml 124 127 124 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D' </italic>
###xml 135 136 135 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 253 256 253 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D' </italic>
###xml 317 324 317 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC1A5 </italic>
###xml 328 335 328 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC6A9 </italic>
###xml 439 446 439 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC1A4 </italic>
###xml 463 470 463 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC6A5 </italic>
###xml 471 474 471 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D' </italic>
###xml 486 489 486 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D' </italic>
We compared the magnitude of LD for all possible pairs of the SNPs in each gene region in controls and cases by calculating D' (Figure 2). No essential difference was shown in the LD pattern of any genes between cases and controls. Strong or modest LD (D' > 0.3) were observed in all combinations of adjacent SNPs in SLC1A5 and SLC6A9 regions. Whereas in each small subregion of the other two gene regions, LD drops abruptly: SNP4-SNP5 of SLC1A4 and SNP2-SNP3 of SLC6A5 (D' = 0.061 and D' = 0.125, respectively).
###end p 35
###begin p 36
###xml 0 111 0 111 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Pairwise LD analyses using GOLD for control (upper diagonal) and case (lower diagonal) haplotypes of each gene.</bold>
###xml 287 289 287 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D'</italic>
Pairwise LD analyses using GOLD for control (upper diagonal) and case (lower diagonal) haplotypes of each gene. The relative location of markers used to construct the haplotypes is represented on the horizontal and vertical axes, which is more clearly depicted in Figure. 1. LD measure, D', is graphically represented adjacent to each GOLD plot (red and dark blue are opposite ends of the scale).
###end p 36
###begin p 37
###xml 76 77 76 77 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 168 175 168 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC1A4 </italic>
###xml 176 178 176 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 204 211 204 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC6A5 </italic>
###xml 212 214 212 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
We constructed pairwise haplotypes for all of the possible SNP pairs (Table 2). We observed significant associations with schizophrenia in combinations of SNP2-SNP7 of SLC1A4 (P = 0.037) and SNP1-SNP4 of SLC6A5 (P = 0.043). However, neither of them survived after controlling the FDR at level 0.05.
###end p 37
###begin p 38
Association analyses of pairwise haplotypes of SNPs in the genes
###end p 38
###begin p 39
###xml 0 2 0 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 30 31 28 29 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
P values by the two-tailed chi2-test (d.f. = 3).
###end p 39
###begin title 40
Association analyses using the Full-size Sample Set
###end title 40
###begin p 41
###xml 226 233 226 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC1A4 </italic>
###xml 257 264 257 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC6A5 </italic>
###xml 355 362 355 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC1A4 </italic>
###xml 440 443 440 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D' </italic>
###xml 512 515 512 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D' </italic>
###xml 527 530 527 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D' </italic>
###xml 663 664 663 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S2">2</xref>
###xml 705 712 705 712 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC6A5 </italic>
###xml 814 816 814 816 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 825 827 825 827 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 905 907 905 907 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 965 967 965 967 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Since nominally significant single-marker and haplotype associations with schizophrenia were observed in the Screening Sample Set, we genotyped the Full-size Sample Set for the SNPs involved in the significance, SNP2, SNP3 of SLC1A4 and SNP1, SNP2, SNP4 of SLC6A5 to examine these significant associations in the Full-size Sample Set. We excluded SNP7 of SLC1A4 from further analyses in the Full-size Sample Set because of the insufficient D' observed in the combination of SNP2-SNP7 in both cases and controls (D' = 0.064 and D' = 0.171, respectively). The genotype and allele frequencies of each SNP in the Full-size Sample Set are shown in the Additional File 2. The significant association of SNP1 of SLC6A5 with schizophrenia was confirmed in both genotype and allele frequencies in the Full-size Sample Set (P = 0.032, P = 0.018, respectively). We failed to detect other single-marker associations (P value range 0.065 - 0.355) and the haplotype association (P = 0.088) observed in the initial screening.
###end p 41
###begin title 42
Discussion
###end title 42
###begin p 43
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC1A4</italic>
###xml 8 14 8 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC1A5</italic>
###xml 16 23 16 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC6A5 </italic>
###xml 27 34 27 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC6A9 </italic>
###xml 180 187 180 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC1A4 </italic>
###xml 286 288 286 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 289 291 289 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 413 420 413 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC1A4 </italic>
###xml 452 454 452 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 494 501 494 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC1A4 </italic>
###xml 559 561 559 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 650 656 650 656 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC1A5</italic>
###xml 658 665 658 665 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC6A5 </italic>
###xml 668 675 668 675 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC6A9 </italic>
###xml 688 690 688 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 750 757 750 757 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC1A5 </italic>
###xml 822 824 822 824 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 898 905 898 905 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC6A9 </italic>
###xml 909 916 909 916 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC6A5 </italic>
###xml 986 988 986 988 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 989 991 989 991 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 1029 1035 1029 1035 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC1A4</italic>
###xml 1037 1043 1037 1043 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC1A5</italic>
###xml 1045 1052 1045 1052 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC6A5 </italic>
###xml 1056 1063 1056 1063 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC6A9 </italic>
SLC1A4, SLC1A5, SLC6A5 and SLC6A9 were located on chromosome 2p13-15, 19q13.3, 11p15.2-p15.1, and 1p33, respectively. Suggestive evidence for linkage of chromosome 2p14-p13, where SLC1A4 is located, with schizophrenia has been reported in schizophrenia families from Palau and Ireland [35,36]. However, the subsequent mutation screening failed to find any sequence polymorphism segregated with the illness in the SLC1A4 region of the Palauan families [37]. In addition, negative association of SLC1A4 with schizophrenia was reported in the German population [38]. There has been no linkage with schizophrenia reported to the chromosome regions where SLC1A5, SLC6A5 or SLC6A9 are located [36]. Moreover, exclusion of linkage between schizophrenia and SLC1A5 in 23 English and Icelandic schizophrenia families was reported [39]. Recently, negative associations of schizophrenia with polymorphisms in SLC6A9 and SLC6A5 were reported in the Chinese and the German population, respectively [40,41]. We investigated the association of SLC1A4, SLC1A5, SLC6A5 and SLC6A9 genes with schizophrenia in the Japanese population by analysing total 21 common SNPs.
###end p 43
###begin p 44
Since the frequencies of genotyped SNPs are over 0.3, the expected detection powers of the four genes are over 0.80, assuming the genotype relative risk of 1.8. However, assuming lower genotype relative risk of 1.5 or 1.3, the expected detection powers for the four genes dropped to 0.50 - 0.53 or 0.24 - 0.25, respectively. Consequently, the negative finding for genes and SNPs excluded from the analyses using the Full-size Sample Set in this study may be due to type II error at lower relative risks, and they need to be investigated further in an enlarged sample size.
###end p 44
###begin p 45
###xml 40 46 40 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC1A4</italic>
###xml 107 113 107 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC6A5</italic>
###xml 246 248 246 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 249 251 249 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 358 365 358 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC6A5 </italic>
Out of the 21 SNPs analyzed, two within SLC1A4, (SNP4 and SNP6, 330 cases and 319 controls) and one within SLC6A5, (SNP5, 328 cases and 307 controls) have recently been reported to show no association with schizophrenia in the German population [38,41]. We also observed no association of these SNPs with the disease in our Screening Sample Set. The SNP1 in SLC6A5 of which we observed a significant association with the disease, was not included in the report mentioned above.
###end p 45
###begin p 46
###xml 97 100 97 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D' </italic>
###xml 213 220 213 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC1A4 </italic>
###xml 237 243 237 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC6A5</italic>
###xml 341 342 341 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 415 417 415 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 450 457 450 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC6A5 </italic>
###xml 557 560 557 560 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D' </italic>
###xml 572 575 572 575 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D' </italic>
###xml 639 646 639 646 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC1A4 </italic>
In LD analysis of the initial screening of the 21 SNPs distributed in the four genes, modest LD (D' > 0.3) was observed in all combinations of adjacent SNPs in controls except for the combinations of SNP4-SNP5 of SLC1A4 and SNP2-SNP3 of SLC6A5, suggesting recombination hot spots in the two regions (6.6 kb and 7.6 kb, respectively) (Figure 2). We compared the LD structure to the publically open database, HapMap [42]. The LD gap we observed in the SLC6A5 region was not observed in the HapMap LD structure from either Japanese or Chinese population data (D' = 0.817 and D' = 1, respectively). The other LD gap, which was observed in the SLC1A4 region, failed to be compared due to the absence of the novel SNP we found.
###end p 46
###begin p 47
###xml 71 78 71 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC1A4 </italic>
###xml 344 351 344 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC6A5 </italic>
###xml 561 563 561 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 819 826 819 826 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC6A5 </italic>
###xml 994 996 994 996 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 1349 1355 1349 1355 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC6A5</italic>
###xml 1365 1379 1365 1379 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC1A4 SLC1A5 </italic>
###xml 1383 1390 1383 1390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC6A9 </italic>
###xml 1579 1581 1579 1581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 1800 1807 1800 1807 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC6A5 </italic>
###xml 1808 1810 1808 1810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 2201 2208 2201 2208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC6A5 </italic>
###xml 1701 1704 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 1867 1870 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 1902 1905 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 2117 2120 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
We observed significant single-marker associations in SNP2 and SNP3 of SLC1A4 in the Screening Sample Set. However, we failed to confirm these findings in the Full-size Sample Set. We attribute to type I error due to the small sample size used in the Screening Sample Set. On the other hand, the single-marker association of SNP1 (rs894747) in SLC6A5 region, although it does not show the significant association with the disease in the independent 300 case and 320 control samples (0.092), it does show the significant association in the Full-size Sample Set (P = 0.018). We consider that the nonsignificant result observed in the enlarged samples may be due to the small sample size. SNP1 is located in the intergenic region, 2,355-bp upstream from the transcription start site. In the negative association report of SLC6A5 in German population described above, four SNPs and one short-tandem-repeat distributed in intron 1~intron 11, but no SNP located in the upstream region were analysed [39]. In our Full-size Sample Set, the G allele was more frequently observed in schizophrenics (44.4%) than in controls (38.6%). Therefore, the G allele may be in LD with a risk allele for schizophrenia (odds ratio, 1.27; 95% confidence interval, 1.04~1.55). We conclude that at least one susceptibility locus for schizophrenia is located within or nearby SLC6A5, whereas SLC1A4 SLC1A5 and SLC6A9 are unlikely to be major susceptibility genes for schizophrenia in the Japanese population. No potential regulatory elements were previously identified in the region where SNP1 is located [43]. It is necessary to search for functional SNPs in the haplotype block where SNP1 is located. A copy number variation (CNV) has been reported in the European population on the chromosome 11p15.1, containing exon 15 of SLC6A5 [44]. None of the 6 SNPs we genotyped is located within the CNV. Although the frequency of the CNV in the Japanese population is unknown, SNP1 may be associated with the variant devoid of exon 15, which is a strong candidate of the susceptible allele. Therefore, it is necessary to test the association of the CNV with schizophenia in Japanese sample sets. The positive association observed in SLC6A5 also needs to be validated in different ethnic populations.
###end p 47
###begin title 48
Conclusion
###end title 48
###begin p 49
###xml 97 103 97 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC6A5</italic>
###xml 113 127 113 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC1A4 SLC1A5 </italic>
###xml 131 138 131 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC6A9 </italic>
We conclude that at least one susceptibility locus for schizophrenia is located within or nearby SLC6A5, whereas SLC1A4 SLC1A5 and SLC6A9 are unlikely to be major susceptibility genes for schizophrenia in the Japanese population.
###end p 49
###begin title 50
Competing interests
###end title 50
###begin p 51
The authors declare that they have no competing interests.
###end p 51
###begin title 52
Authors' contributions
###end title 52
###begin p 53
XD carried out a portion of genotyping, statistical analyses and drafted the manuscript; NS, NT, MT carried out a portion of genotyping and statistical analyses; HN, NI and NO participated in collecting specimens and clinical data; HS participated in design of this study and statistical analyses; YF conceived of the study and participated in its design and coordination. All authors read and approved the final manuscript.
###end p 53
###begin title 54
Pre-publication history
###end title 54
###begin p 55
The pre-publication history for this paper can be accessed here:
###end p 55
###begin p 56

###end p 56
###begin title 57
Supplementary Material
###end title 57
###begin title 58
Additional file 1
###end title 58
###begin p 59
PCR primers for genotyping of SNPs in the genes. The data provided the nucleotide sequences of primers, PCR conditions and genotyping methods for each SNP.
###end p 59
###begin p 60
Click here for file
###end p 60
###begin title 61
Additional file 2
###end title 61
###begin p 62
Genotype and allele frequencies of SNPs in the Full-size Sample Set (400 cases and 420 controls). The data show genotype and allele frequencies of SNPs in the Full-size Sample Set.
###end p 62
###begin p 63
Click here for file
###end p 63
###begin title 64
Acknowledgements
###end title 64
###begin p 65
We are grateful to all the medical staff involved in collecting specimens, especially to Dr. Nobutada Tashiro, the emeritus professor of Kyushu University Graduate School of Medical Science for the initial support to our project. This work was supported by KAKENHI (Grant-in-Aid for Scientific Research) on Priority Areas "Applied Genomics" and other grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan and by The Naito Foundation Subsidy for Natural Science Researches.
###end p 65
###begin article-title 66
Genetic basis of schizophrenia
###end article-title 66
###begin article-title 67
Study of a new schizophrenomimetic drug, sernyl
###end article-title 67
###begin article-title 68
Recent advances in the phencyclidine model of schizophrenia
###end article-title 68
###begin article-title 69
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice with reduced NMDA receptor expression display behaviors related to schizophrenia
###end article-title 69
###begin article-title 70
Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence
###end article-title 70
###begin article-title 71
Molecular genetic studies of schizophrenia
###end article-title 71
###begin article-title 72
Dopamine-glutamate interaction and antipsychotics mechanism of action: implication for new pharmacological strategies in psychosis
###end article-title 72
###begin article-title 73
Expression of excitatory amino acid transporter transcripts in the thalamus of subjects with schizophrenia
###end article-title 73
###begin article-title 74
Increased expression of the astrocytic glutamate transporter GLT-1 in the prefrontal cortex of schizophrenics
###end article-title 74
###begin article-title 75
Gene expression of metabotropic glutamate receptor 5 and excitatory amino acid transporter 2 in the schizophrenic hippocampus
###end article-title 75
###begin article-title 76
Striatal excitatory amino acid transporter transcript expression in schizophrenia, bipolar disorder, and major depressive disorder
###end article-title 76
###begin article-title 77
###xml 84 90 84 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC1A2</italic>
Association study of polymorphisms in the excitatory amino acid transporter 2 gene (SLC1A2) with schizophrenia
###end article-title 77
###begin article-title 78
###xml 70 76 70 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC1A1</italic>
###xml 78 84 78 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC1A3</italic>
###xml 90 97 90 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC1A6 </italic>
Association study of polymorphisms in the glutamate transporter genes SLC1A1, SLC1A3, and SLC1A6 with schizophrenia
###end article-title 78
###begin article-title 79
###xml 28 33 <span type="species:ncbi:9606">human</span>
Cloning and expression of a human neutral amino acid transporter with structural similarity to the glutamate transporter gene family
###end article-title 79
###begin article-title 80
Cloning and functional characterization of a system ASC-like Na+dependent neutral amino acid transporter
###end article-title 80
###begin article-title 81
###xml 73 76 <span type="species:ncbi:10116">rat</span>
Ontogeny and localization of the neutral amino acid transporter ASCT1 in rat brain
###end article-title 81
###begin article-title 82
###xml 111 116 <span type="species:ncbi:10090">mouse</span>
Neutral amino acid transporter ASCT1 is preferentially expressed in L-Ser-synthetic/storing glial cells in the mouse brain with transient expression in developing capillaries
###end article-title 82
###begin article-title 83
###xml 122 125 <span type="species:ncbi:10116">rat</span>
Functional identification of ASCT1 neutral amino acid transporter as the predominant system for the uptake of L-serine in rat neurons in primary culture
###end article-title 83
###begin article-title 84
The astroglial ASCT2 amino acid transporter as a mediator of glutamine efflux
###end article-title 84
###begin article-title 85
Changes in region- and cell type-specific expression patterns of neutral amino acid transporter 1 (ASCT-1) in the anterior cingulate cortex and hippocampus in schizophrenia, bipolar disorder and major depression
###end article-title 85
###begin article-title 86
Two glycine transporter variants with distinct localization in the CNS and peripheral tissues are encoded by a common gene
###end article-title 86
###begin article-title 87
Glutamate-based therapeutic approaches: inhibitors of glycine transport
###end article-title 87
###begin article-title 88
A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies
###end article-title 88
###begin article-title 89
dbSNP database
###end article-title 89
###begin article-title 90
###xml 29 34 <span type="species:ncbi:9606">human</span>
Linkage disquilibrium in the human genome
###end article-title 90
###begin article-title 91
###xml 71 76 71 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GRIK1</italic>
Association study of polymorphisms in the GluR5 kainate receptor gene (GRIK1) with schizophrenia
###end article-title 91
###begin article-title 92
Polyphred: substitutions using fluorescence-based resequencing
###end article-title 92
###begin article-title 93
Testing linkage disequilibrium between a disease gene and marker loci
###end article-title 93
###begin article-title 94
GOLD: graphical overview of linkage disequilibrium
###end article-title 94
###begin article-title 95
Controlling the false discovery rate in behavior genetics research
###end article-title 95
###begin article-title 96
The power of genome-wide association studies of complex disease genes: statistical limitations of indirect approaches using SNP markers
###end article-title 96
###begin article-title 97
Evidence for a chromosome 2p13-14 schizophrenia susceptibility locus in families from Palau, Micronesia
###end article-title 97
###begin article-title 98
Genome-wide scans of three independent sets of 90 Irish multiplex schizophrenia families and follow-up of selected regions in all families provides evidence for multiple susceptibility genes
###end article-title 98
###begin article-title 99
Mutation screening of a neutral amino acid transporter, ASCT1, and its potential role in schizophrenia
###end article-title 99
###begin article-title 100
No association between genetic variants at the ASCT1 gene and schizophrenia or bipolar disorder in a German sample
###end article-title 100
###begin article-title 101
###xml 119 125 119 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC1A5</italic>
Exclusion of linkage between schizophrenia and the gene encoding a neutral amino acid glutamate/aspartate transporter, SLC1A5
###end article-title 101
###begin article-title 102
Association study of polymorphisms in glycine transporter with schizophrenia
###end article-title 102
###begin article-title 103
No association between genetic variants at the GLYT2 gene and bipolar affective disorder and schizophrenia
###end article-title 103
###begin article-title 104
HapMap database
###end article-title 104
###begin article-title 105
###xml 41 44 <span type="species:ncbi:10116">rat</span>
Characterization of the 5' region of the rat brain glycine transporter GLYT2 gene: identification of a novel isoform
###end article-title 105
###begin article-title 106
###xml 66 71 <span type="species:ncbi:9606">human</span>
An initial map of insertion and deletion (INDEL) variation in the human genome
###end article-title 106

